A New Horizon for Primary Invasive Pulmonary Aspergillosis Treatment

Wednesday, January 18, 2017 | 3:00 p.m. - 4:00 p.m. Add to Calendar

Invasive pulmonary aspergillosis (IPA) is an opportunistic infection that has a high mortality rate (approximately 40 percent). The Infectious Disease Society of America currently recommends voriconazole as the primary treatment option for IPA. However, voriconazole has a number of limitations that make it a less-than-ideal drug. Newer treatment strategies (isavuconazole and combination therapy) have the potential to improve upon these limitations, but their exact role in IPA is still uncertain. The purpose of this presentation is to identify when to use voriconazole, isavuconazole, and combination therapy in the treatment of primary IPA. The seminar will be presented by Benjamin Casey, Pharm.D., UHCOP/Cardinal Health PGY2 Infectious Diseases Pharmacotherapy resident.


UH College of Pharmacy TMC Campus

1441 Moursund, Room 218, Houston, TX


Amelia Sofjan